IL-7 (human):Fc (human) (rec.) (non-lytic)
The extracellular domain of human IL-7 (aa 26-177) is fused to the N-terminus of the Fc portion of a mutant human IgG1.
Measured in a cell proliferation assay using antibody against CD3-activated human peripheral blood lymphocytes (PBL). The ED50 for this effect is typically 10-100ng/ml.
|Endotoxin Content||<1EU/mg protein (LAL test; Lonza).|
Reconstitute 50µg vial in 50µl sterile water.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
NCBI reference AAH47698.1: IL-7 (human)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Interleukin-7 (IL-7), is a hematopoietic growth factor and a member of the IL-7/IL-9 family. IL-7 stimulates the proliferation of lymphoid progenitors and is secreted by stromal cells in the bone marrow and thymus. IL-7 is also important for proliferation during certain stages of B cell maturation. IL-7 and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. It is found to be a cofactor for V(D)J rearrangement of the T cell receptor β (TCRβ) during early T cell development. IL-7 can be produced locally by intestinal epithelial and epithelial goblet cells and may serve as a regulatory factor for intestinal mucosal lymphocytes.
- IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model: E.M. Yu, et al.; Cells 10, (2021)
- Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells: SH. Kim, et al.; Nat. Commun. 12, 5314 (2021)